Research and Progress of Probucol in Nonalcoholic Fatty Liver Disease

被引:2
作者
Chen, Ke-qian [1 ,2 ]
Ke, Bo-yi [1 ,2 ]
Cheng, Lu [1 ,2 ]
Guan, Meng-ting [1 ,2 ]
Wang, Zong-bao [1 ,2 ]
Wang, Shu-zhi [1 ,2 ]
机构
[1] Univ South China, Hengyang Med Sch, Sch Pharmaceut Sci, Inst Pharm & Pharmacol, Hengyang 421001, Peoples R China
[2] Univ South China, Hunan Prov Cooperat Innovat Ctr Mol Target New Dru, Hengyang 421001, Peoples R China
关键词
Non-alcoholic fatty liver disease; probucol; non-alcoholic steatohepatitis steatosis; fibrosis; mitochondrial dysfunction; (HDL-C); OXIDATIVE STRESS; LOWERING DRUG; OPEN-LABEL; STEATOHEPATITIS; EXPRESSION; PROTECTS; RATS; ATHEROSCLEROSIS; NEPHROPATHY; PREVENTS;
D O I
10.2174/1389557523666230324092842
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
With the development of the social economy over the last 30 years, non-alcoholic fatty liver disease (NAFLD) is affected by unhealthy living habits and eating styles and has gradually become an increasingly serious public health problem. It is very important to investigate the pathogenesis and treatment of NAFLD for the development of human health. Probucol is an antioxidant with a bis-phenol structure. Although probucol is a clinically used cholesterol-lowering and anti-atherosclerosis drug, its mechanism has not been elucidated in detail. This paper reviews the chemical structure, pharmacokinetics and pharmacological research of probucol. Meanwhile, this paper reviews the mechanism of probucol in NAFLD. We also analyzed and summarized the experimental models and clinical trials of probucol in NAFLD. Although current therapeutic strategies for NAFLD are not effective, we hope that through further research on probucol, we will be able to find suitable treatments to solve this problem in the future.
引用
收藏
页码:1905 / 1911
页数:7
相关论文
共 56 条
[1]   Ageing Fxr Deficient Mice Develop Increased Energy Expenditure, Improved Glucose Control and Liver Damage Resembling NASH [J].
Bjursell, Mikael ;
Wedin, Marianne ;
Admyre, Therese ;
Hermansson, Majlis ;
Bottcher, Gerhard ;
Goransson, Melker ;
Linden, Daniel ;
Bamberg, Krister ;
Oscarsson, Jan ;
Bohlooly-Y, Mohammad .
PLOS ONE, 2013, 8 (06)
[2]   Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis [J].
Carlsson, Bjorn ;
Linden, Daniel ;
Brolen, Gabriella ;
Liljeblad, Mathias ;
Bjursell, Mikael ;
Romeo, Stefano ;
Loomba, Rohit .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 51 (12) :1305-1320
[3]   Synergistic Effects of Cilostazol and Probucol on ER Stress-Induced Hepatic Steatosis via Heme Oxygenase-1-Dependent Activation of Mitochondrial Biogenesis [J].
Chen, Yingqing ;
Pandiri, Indira ;
Joe, Yeonsoo ;
Kim, Hyo Jeong ;
Kim, Seul-Ki ;
Park, Jeongmin ;
Ryu, Jinhyun ;
Cho, Gyeong Jae ;
Park, Jeong Woo ;
Ryter, Stefan W. ;
Chung, Hun Taeg .
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2016, 2016
[4]   FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption [J].
Clifford, Bethan L. ;
Sedgeman, Leslie R. ;
Williams, Kevin J. ;
Morand, Pauline ;
Cheng, Angela ;
Jarrett, Kelsey E. ;
Chan, Alvin P. ;
Brearley-Sholto, Madelaine C. ;
Wahlstrom, Annika ;
Ashby, Julianne W. ;
Barshop, William ;
Wohlschlegel, James ;
Calkin, Anna C. ;
Liu, Yingying ;
Thorell, Anders ;
Meikle, Peter J. ;
Drew, Brian G. ;
Mack, Julia J. ;
Marschall, Hanns-Ulrich ;
Tarling, Elizabeth J. ;
Edwards, Peter A. ;
Vallim, Thomas Q. de Aguiar .
CELL METABOLISM, 2021, 33 (08) :1671-+
[5]  
Converso DP, 2006, FASEB J, V20, P1236, DOI 10.1096/fj.05-4204fje
[6]   Targeting farnesoid X receptor for liver and metabolic disorders [J].
Fiorucci, Stefano ;
Rizzo, Gianni ;
Donini, Annibale ;
Distrutti, Eleonora ;
Santucci, Luca .
TRENDS IN MOLECULAR MEDICINE, 2007, 13 (07) :298-309
[7]   PHARMACOKINETICS OF PROBUCOL IN MALE-RATS [J].
HEEG, JF ;
HISER, MF ;
SATONIN, DK ;
ROSE, JQ .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1984, 73 (12) :1758-1763
[8]   Probucol-Induced α-Tocopherol Deficiency Protects Mice against Malaria Infection [J].
Herbas, Maria Shirely ;
Shichiri, Mototada ;
Ishida, Noriko ;
Kume, Aiko ;
Hagihara, Yoshihisa ;
Yoshida, Yasukazu ;
Suzuki, Hiroshi .
PLOS ONE, 2015, 10 (08)
[9]   Probucol Slows the Progression of Cataracts in Streptozotocin-Induced Hyperglycemic Rats [J].
Higashi, Kentaro ;
Mori, Asami ;
Sakamoto, Kenji ;
Ishii, Kunio ;
Nakahara, Tsutomu .
PHARMACOLOGY, 2019, 103 (3-4) :212-219
[10]   Probucol, a "non-statin" cholesterol-lowering drug, ameliorates D-galactose induced cognitive deficits by alleviating oxidative stress via Keap1/Nrf2 signaling pathway in mice [J].
Huang, Jin-Lan ;
Yu, Chao ;
Su, Min ;
Yang, Si-Man ;
Zhang, Fan ;
Chen, Yuan-Yuan ;
Liu, Jin-Yuan ;
Jiang, Yi-Fan ;
Zhong, Zhen-Guo ;
Wu, Deng-Pan .
AGING-US, 2019, 11 (19) :8542-8555